JP2018515474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515474A5 JP2018515474A5 JP2017556652A JP2017556652A JP2018515474A5 JP 2018515474 A5 JP2018515474 A5 JP 2018515474A5 JP 2017556652 A JP2017556652 A JP 2017556652A JP 2017556652 A JP2017556652 A JP 2017556652A JP 2018515474 A5 JP2018515474 A5 JP 2018515474A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- weeks
- administered
- tissue sample
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 201000001441 melanoma Diseases 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 210000004969 inflammatory cell Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037372A JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153954P | 2015-04-28 | 2015-04-28 | |
| US62/153,954 | 2015-04-28 | ||
| PCT/US2016/029878 WO2016176504A1 (en) | 2015-04-28 | 2016-04-28 | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037372A Division JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515474A JP2018515474A (ja) | 2018-06-14 |
| JP2018515474A5 true JP2018515474A5 (enExample) | 2019-06-13 |
Family
ID=56069213
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556652A Pending JP2018515474A (ja) | 2015-04-28 | 2016-04-28 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2021037372A Pending JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A Pending JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037372A Pending JP2021105001A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2024018859A Pending JP2024063028A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20160362489A1 (enExample) |
| EP (1) | EP3288980B1 (enExample) |
| JP (3) | JP2018515474A (enExample) |
| KR (2) | KR20250107941A (enExample) |
| ES (1) | ES2861352T3 (enExample) |
| WO (1) | WO2016176504A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| MY187739A (en) | 2015-08-11 | 2021-10-18 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN108350081A (zh) * | 2015-11-18 | 2018-07-31 | 百时美施贵宝公司 | 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌 |
| EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| EP3589652B1 (en) * | 2017-03-04 | 2024-12-25 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor |
| IL269026B2 (en) * | 2017-03-31 | 2024-12-01 | Bristol Myers Squibb Co | Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients |
| CN110505882A (zh) * | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| KR102713203B1 (ko) | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| KR20240155979A (ko) | 2017-05-30 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| EP3421607A1 (en) * | 2017-06-29 | 2019-01-02 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Identification and elimination of damaged and/or senescent cells |
| KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| WO2019084313A1 (en) * | 2017-10-27 | 2019-05-02 | Board Of Regents, The University Of Texas System | USE OF SDHA AS PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR UREAL MELANOMA |
| JP2021506968A (ja) * | 2017-12-18 | 2021-02-22 | デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． | 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用 |
| SG11202007590TA (en) | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| WO2019182981A1 (en) | 2018-03-21 | 2019-09-26 | Olatec Therapeutics Llc | Methods for treating melanoma |
| JP7467438B2 (ja) | 2018-10-18 | 2024-04-15 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｒｓｖ抗体の製剤及びその使用方法 |
| CN113015748B (zh) | 2018-10-31 | 2025-12-12 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| AU2019374748A1 (en) * | 2018-11-05 | 2021-05-27 | Merck Sharp & Dohme Llc | Dosing regimen of anti-LAG3 antibody and combination therapy with anti-PD-1 antibody for treating cancer |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| WO2020118208A1 (en) * | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
| EP3908285A4 (en) | 2019-01-07 | 2022-10-19 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| AU2021364837A1 (en) | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| US12258411B2 (en) * | 2021-06-04 | 2025-03-25 | Amgen Inc. | Anti-CCR8 antibodies and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| SI3508502T1 (sl) * | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| KR20170052569A (ko) * | 2014-07-18 | 2017-05-12 | 어드박시스, 인크. | 전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용 |
| BR112017008914A2 (pt) * | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
| JP2018500332A (ja) * | 2014-12-16 | 2018-01-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| UY36687A (es) * | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| KR20180101584A (ko) * | 2016-01-27 | 2018-09-12 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료 |
| WO2019067913A1 (en) * | 2017-09-29 | 2019-04-04 | Bristol-Myers Squibb Company | COMPOSITIONS AND METHODS OF TREATING CANCER |
-
2016
- 2016-04-28 ES ES16724512T patent/ES2861352T3/es active Active
- 2016-04-28 US US15/141,772 patent/US20160362489A1/en not_active Abandoned
- 2016-04-28 EP EP16724512.5A patent/EP3288980B1/en active Active
- 2016-04-28 WO PCT/US2016/029878 patent/WO2016176504A1/en not_active Ceased
- 2016-04-28 KR KR1020257021485A patent/KR20250107941A/ko active Pending
- 2016-04-28 KR KR1020177033883A patent/KR20170140316A/ko not_active Ceased
- 2016-04-28 JP JP2017556652A patent/JP2018515474A/ja active Pending
-
2019
- 2019-06-03 US US16/430,106 patent/US20200010549A1/en not_active Abandoned
-
2021
- 2021-03-09 JP JP2021037372A patent/JP2021105001A/ja active Pending
-
2022
- 2022-03-22 US US17/701,436 patent/US20220281974A1/en active Pending
-
2024
- 2024-02-09 JP JP2024018859A patent/JP2024063028A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515474A5 (enExample) | ||
| JP2018514550A5 (enExample) | ||
| JP2018522887A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2018520657A5 (enExample) | ||
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| JP2016500251A5 (enExample) | ||
| WO2018187613A3 (en) | Anti-icos agonist antibodies and uses thereof | |
| HRP20230237T1 (hr) | Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018501197A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2020500542A5 (enExample) | ||
| JP2017508475A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017518366A5 (enExample) | ||
| JP2016537383A5 (enExample) | ||
| JP2017500057A5 (enExample) |